Company Overview and News

1
Bulletproof Investing Performance: Week 20

2018-04-13 seekingalpha
It's been six months since I presented three hedged portfolios and 10 top names in week 20 of my Marketplace service (October 12th). Here's how everything did.

 
Infrastructure And Energy Alternatives: Wind At Their Back With 25% FCF Yield

2018-04-06 seekingalpha
IEA is an undiscovered, newly public renewables focused E&C company with a compelling valuation – 3.8x 2018 EV/EBITDA and a free cash flow yield of around 25% and record backlog.

 
10 Stocks That Are Screaming Buys Right Now

2018-04-05 investorplace
Buckle up — the market is looking jittery right now. If it’s not the threat of further Federal interest rate hikes, it’s the possibility of a full-blown trade war with China and Europe. Most recently, President Donald Trump announced steep tariffs on steel and aluminum imports. The news saw the S&P 500 close down 2% last week. This is nearly twice as much as any decline in 2017.

 
MasTec (MTZ) Announces $100M Share Repurchase Authorization

2018-04-02 zacks
MasTec, Inc. (MTZ - Free Report) recently announced the completion of its previously authorized $100-million share-repurchase program. The company has also approved a new buyback program of up to $100 million shares which reflects its commitment to generate long-term value for shareholders. The previous repurchase plan was authorized in February 2016. The new program does not have any expiry date and is expected to be made in the open market via private off-market transactions per the Securities and Exchange Commission’s guidelines.

 
Why Is MasTec (MTZ) Down 10.7% Since its Last Earnings Report?

2018-03-29 zacks
It has been about a month since the last earnings report for MasTec, Inc. (MTZ - Free Report) . Shares have lost about 10.7% in that time frame.

 
MTZ / MasTec, Inc. DEF 14A

2018-03-28 sec.gov
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

1
The 7 Best Stocks from Each Sector Through Q2

2018-03-26 investorplace
We are now rolling into the second quarter of 2018. So far this year the markets have been undeniably jumpy. Just last week global markets posted sharp losses as talk of a trade war continues to spook investors. But for the stocks listed below 2018 hasn’t been so bad at all.

3
10 Stocks That Are Screaming Buys Right Now | InvestorPlace

2018-03-07 investorplace
Buckle up — the market is looking jittery right now. If it’s not the threat of further Federal interest rate hikes, its the possibility of a full-blown trade war with China and Europe. Most recently, President Donald Trump announced steep tariffs on steel and aluminum imports. The news saw the S&P 500 close down 2% last week. This is nearly twice as much as any decline in 2017.

 
Chicago Bridge & Iron Awarded CDAlky Technology Contract

2018-03-02 zacks
Chicago Bridge & Iron Company N.V. (CBI - Free Report) recently announced that Valero Refining – New Orleans LLC has selected its CDAlky technology for the Valero’s St. Charles Alkylation Project in Norco, Louisiana. The new CDAlky unit is expected to produce 25,000 BPD alkylate from FCC-derived olefin feedstocks, once it becomes functional in 2020.

 
Bull of the Day: MasTec (MTZ)

2018-03-02 zacks
I last wrote about MasTec (MTZ - Free Report) as the Bull of the Day on February 6 as earnings estimates and price targets were rising before their quarterly report this week. The $3.75 billion E&C services (engineering & construction) provider for telecom and energy companies delivered record fourth-quarter 2017 adjusted earnings per share of 47-cents, beating the Zacks Consensus Estimate of 37-cents by 27%.

 
MasTec, NutriSystem and Nutanix highlighted as Zacks Bull and Bear of the Day

2018-03-02 zacks
Chicago, IL – March 2, 2018 – Zacks Equity Research highlights MasTec (MTZ - Free Report) as the Bull of the Day, NutriSystem (NTRI - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Nutanix, Inc. (NTNX - Free Report) .

 
Zacks.com highlights: Arkema SA, GP Strategies, Commercial Vehicle Group, MasTec and Modine Manufacturing

2018-03-02 zacks
Chicago, IL – March 2, 2018 - Stocks in this week’s article include: Arkema SA (ARKAY - Free Report) , GP Strategies Corporation (GPX - Free Report) , Commercial Vehicle Group Inc. (CVGI - Free Report) , MasTec Inc. (MTZ - Free Report) and Modine Manufacturing Company (MOD - Free Report) .

 
Dycom (DY) Q2 Earnings Beat, Enjoys Robust Industry Trends

2018-03-02 zacks
Dycom Industries Inc. (DY - Free Report) continued its winning streak for the eighth consecutive quarter as its second-quarter fiscal 2018 adjusted earnings of 12 cents per share surpassed the Zacks Consensus Estimate by 9.1%. The bottom line also came in at the higher end of the recently projected range of 9-12 cents.

 
5 Top Stocks With Striking Net Profit Margin

2018-03-01 zacks
The primary motive of any investor is to generate maximum returns. Thus, investors are always on the lookout for companies that are raking in huge profits. Net profit margin is the most effective way to measure a company’s profitability. A proper analysis of the same reveals how well a company is functioning and the headwinds confronting it. Net Profit Margin = Net profit /Sales * 100. In simple terms, net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.

 
Zacks Investment Ideas feature highlights: MasTec, Lam Research, NVIDIA, Apple and Square

2018-03-01 zacks
Chicago, IL – March 1, 2018 – Today, Zacks Investment Ideas feature highlights Features: MasTec (MTZ - Free Report) ), Lam Research (LRCX - Free Report) ), NVIDIA (NVDA - Free Report) ), Apple (AAPL - Free Report) ) and Square (SQ - Free Report) .

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 576323109